Disclosed is a novel fused bicyclic compound [I] shown below, which has affinityfor a mineralcorticoid receptor (MR) and is useful as an anti-hypertensive agentor the like. Specifically disclosed is a compound represented by the formula[I] or a pharmacologically acceptable salt thereof. [I] whereinthe ring A represents a benzene ring which is fused with the adjacent heterocyclic6-membered ring and has a substituent R, and which may have a substituentother than R； R represents an alkylsulfonylamino groupor the like； R and R (a) independently represent a hydrogen,an alkyl or a substituted or unsubstituted aryl, (b) together form an oxo, or (c)together with the adjacent carbon atom, form a cycloalkyl； X represents =N-,=C(R)- or -CH(R)-； R represents (a) a hydrogen,(b) a cyano, (c) a halogen, (d) an alkyl, (e) an alkenyl, (f) a cycloalkyl, (g) analkanoyl, (h) a carbamoyl or (i) a cycloalkenyl； Ar represents a substitutedor unsubstituted aromatic cyclic group； and a dotted line means the presenceor absence of a double bond.
